{"disease":{"id":"anticoagulant-induced-prothrombin-deficiency","name":"Anticoagulant-Induced Prothrombin Deficiency","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"vitamin-k1","indication_name":"Anticoagulant-induced prothrombin deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"phytonadione","indication_name":"Anticoagulant-induced prothrombin deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PHYTONADIONE","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1 (VKORC1)","drug_class":"Vitamin K [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"vitamin-k1","indication_name":"Anticoagulant-induced prothrombin deficiency caused by coumarin derivatives","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"vitamin-k1","indication_name":"Anticoagulant-induced prothrombin deficiency caused by indanedione derivatives","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"phytomenadione","indication_name":"Anticoagulant-Induced Prothrombin Deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phytomenadione","company_name":"Instituto Mexicano del Seguro Social","drug_phase":"phase_2","molecular_target":"Alpha-synuclein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"phytonadione","indication_name":"Anticoagulant-induced prothrombin deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PHYTONADIONE","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1 (VKORC1)","drug_class":"Vitamin K [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"phylloquinone","indication_name":"Anticoagulant-Induced Prothrombin Deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Phylloquinone","company_name":"Guy's and St Thomas' NHS Foundation Trust","drug_phase":"phase_2","molecular_target":"Alpha-synuclein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"vitamin-k1","guideline_body":"FDA label","recommendation":"Phytonadione injectable emulsion is indicated for hypoprothrombinemia due to antibacterial therapy.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null},{"drug_id":"vitamin-k1","guideline_body":"FDA label","recommendation":"Phytonadione injectable emulsion is indicated for anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null},{"drug_id":"vitamin-k1","guideline_body":"FDA label","recommendation":"Phytonadione injectable emulsion is indicated for the prophylaxis and therapy of hemorrhagic disease of the newborn.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null},{"drug_id":"vitamin-k1","guideline_body":"FDA label","recommendation":"Phytonadione injectable emulsion is indicated for hypoprothrombinemia secondary to factors limiting absorption or synthesis of Vitamin K, such as obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null},{"drug_id":"vitamin-k1","guideline_body":"FDA label","recommendation":"Phytonadione injectable emulsion is indicated for other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with phytonadione injectable emulsion metabolism, such as with salicylates.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null}],"source":"Drug Landscape verified database"}